the coda collaborative
TRANSCRIPT
![Page 1: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/1.jpg)
NIH Collaboratory Grand Rounds, November 6, 2020
The CODA Collaborative
![Page 2: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/2.jpg)
NIH Collaboratory Grand Rounds, November 6, 2020
Presented on behalf of the CODA Collaborative by;
David R. Flum, MD MPH
Department of Surgery
University of Washington
Seattle, WA
The CODA Collaborative
![Page 3: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/3.jpg)
CODA Collaborative
East Coast: Bellevue Hospital Center New York
University School of MedicineTisch Hospital New York University
Langone Medical CenterBeth Israel Deaconess Medical Center
Boston University Medical CenterColumbia University Medical Center
Weill Cornell MedicineMaine Medical Center
South: University of Mississippi
Vanderbilt Medical CenterUniversity of Texas Lyndon B. Johnson General HospitalUniversity of Texas Health Science Center at Houston
Midwest: University of Michigan
The Ohio State University WexnerMedical Center
Henry Ford Health SystemsUniversity of Iowa
Rush University Medical Center
West: University of Washington Medical Center
Harborview Medical CenterVirginia Mason Medical Center
Swedish Medical Center- First HillProvidence Regional Medical Center
Madigan Army Medical CenterHarbor-University of California Los
Angeles Medical CenterOlive View-University of California Los
Angeles Medical CenterUniversity of Colorado Denver
![Page 4: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/4.jpg)
CODA: Site InvestigatorsBellevue NYU School of MedicineOnaona Gurney, MDWilliam Chiang, MDPatricia Ayoung-Chee, MD, MPH
Beth Israel Deaconess Medical CenterCharles Parsons, MDNathan Shapiro, MD, MPH
Boston University Medical CenterThurston Drake, MD, MPH Sabrina Sanchez, MD, MPH
Columbia University Medical CenterKatherine Fischkoff, MDAleksandr Tichter, MD, MS
Harbor-UCLA Medical CenterDaniel A. DeUgarte, MDAmy Kaji, MD, PhD
Harborview Medical CenterJoe Cuschieri, MDAmber K Sabbatini, MD, MPHHeather Evans, MD
Henry Ford Health HospitalJeffrey Johnson, MD Joe Patton, MD
Madigan Army Medical Center Vance Sohn, MDKaren McGrane, MD
Maine Medical CenterDamien Carter, MD
The Ohio State University Jon Wisler, MDAmy Rushing, MD
Olive View-UCLA Medical CenterDarin Saltzman, MD, PhDDavid Talan, MD Gregory Moran, MD
Providence Regional Medical Center Careen Foster, MDBrandon Tudor, MD
Rush University Medical CenterThea P Price, MD
Swedish Medical CenterKatherine Mandell, MD, MPH
Tisch NYU Langone Medical CenterOnaona Gurney, MDWilliam Chiang, MD
UCHealth University of Colorado Lisa Ferrigno, MD, MPHMatthew Salzberg, MD, MBA
University of Iowa HealthcareDionne Skeete, MDBrett Faine, PharmD, MS
University of Michigan Medical CenterPauline Park, MDHasan Alam, MD
University of Mississippi Matthew Kutcher, MD, MSAlan Jones, MD
University of Texas at HoustonLillian Kao, MD, MS
University of Texas LBJMike Liang, MD
University of WashingtonGiana H. Davidson, MD, MPHAmber K Sabbatini, MD, MPHDavid R. Flum, MD MPH
Vanderbilt University Medical CenterWesley Self, MD, MPHCallie Thompson, MD
Virginia Mason Medical CenterAbigal Wiebusch, MDJuliana Yu, MD
Weill Cornell Medical CenterRobert Winchell, MDSunday Clark, ScD, MPH
Co-PI
![Page 5: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/5.jpg)
CODA: Site InvestigatorsBellevue NYU School of MedicineOnaona Gurney, MDWilliam Chiang, MDPatricia Ayoung-Chee, MD, MPH
Beth Israel Deaconess Medical CenterCharles Parsons, MDNathan Shapiro, MD, MPH
Boston University Medical CenterThurston Drake, MD, MPH Sabrina Sanchez, MD, MPH
Columbia University Medical CenterKatherine Fischkoff, MDAleksandr Tichter, MD, MS
Harbor-UCLA Medical CenterDaniel A. DeUgarte, MDAmy Kaji, MD, PhD
Harborview Medical CenterJoe Cuschieri, MDAmber K Sabbatini, MD, MPHHeather Evans, MD
Henry Ford Health HospitalJeffrey Johnson, MD Joe Patton, MD
Madigan Army Medical Center Vance Sohn, MDKaren McGrane, MD
Maine Medical CenterDamien Carter, MD
The Ohio State University Jon Wisler, MDAmy Rushing, MD
Olive View-UCLA Medical CenterDarin Saltzman, MD, PhDDavid Talan, MD Gregory Moran, MD
Providence Regional Medical Center Careen Foster, MDBrandon Tudor, MD
Rush University Medical CenterThea P Price, MD
Swedish Medical CenterKatherine Mandell, MD, MPH
Tisch NYU Langone Medical CenterOnaona Gurney, MDWilliam Chiang, MD
UCHealth University of Colorado Lisa Ferrigno, MD, MPHMatthew Salzberg, MD, MBA
University of Iowa HealthcareDionne Skeete, MDBrett Faine, PharmD, MS
University of Michigan Medical CenterPauline Park, MDHasan Alam, MD
University of Mississippi Matthew Kutcher, MD, MSAlan Jones, MD
University of Texas at HoustonLillian Kao, MD, MS
University of Texas LBJMike Liang, MD
University of WashingtonGiana H. Davidson, MD, MPHAmber K Sabbatini, MD, MPHDavid R. Flum, MD MPH
Vanderbilt University Medical CenterWesley Self, MD, MPHCallie Thompson, MD
Virginia Mason Medical CenterAbigal Wiebusch, MDJuliana Yu, MD
Weill Cornell Medical CenterRobert Winchell, MDSunday Clark, ScD, MPH
Co-PI
Co-PI
![Page 6: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/6.jpg)
No conflicts of interest reported
![Page 7: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/7.jpg)
![Page 8: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/8.jpg)
Appendectomy Research
![Page 9: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/9.jpg)
Appendicitis Research
![Page 10: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/10.jpg)
Appendicitis Research
![Page 11: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/11.jpg)
Appendicitis Research
![Page 12: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/12.jpg)
Appendicitis Research
![Page 13: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/13.jpg)
Appendicitis Research
![Page 14: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/14.jpg)
Appendicitis Research
![Page 15: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/15.jpg)
Appendicitis Research
![Page 16: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/16.jpg)
The Evidence
![Page 17: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/17.jpg)
The Evidence
• N=1,724
![Page 18: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/18.jpg)
The Evidence
• N=1,724
• Outcomes common to both treatment arms─ Complications, pain and days away from work-all more for surgery
![Page 19: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/19.jpg)
The Evidence
• N=1,724
• Outcomes common to both treatment arms─ Complications, pain and days away from work-all more for surgery
• Outcomes unique to antibiotics arm
![Page 20: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/20.jpg)
The Evidence
• N=1,724
• Outcomes common to both treatment arms─ Complications, pain and days away from work-all more for surgery
• Outcomes unique to antibiotics arm─ 25-40% of those randomized to antibiotics had appendectomy by 1 yr
![Page 21: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/21.jpg)
The Evidence
• N=1,724
• Outcomes common to both treatment arms─ Complications, pain and days away from work-all more for surgery
• Outcomes unique to antibiotics arm─ 25-40% of those randomized to antibiotics had appendectomy by 1 yr
─ Largest study (APPAC, n=257 antibiotics) • 27% by 1 year
• 39% by 5 years
![Page 22: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/22.jpg)
Evidence Gaps
![Page 23: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/23.jpg)
Evidence Gaps
• “Selected” patients─ Surgeons determined who was approached─ None with CT perforation or appendicolith─ Perforation rate in surgical arm of APPAC <2%
![Page 24: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/24.jpg)
Evidence Gaps
• “Selected” patients─ Surgeons determined who was approached─ None with CT perforation or appendicolith─ Perforation rate in surgical arm of APPAC <2%
•Not typical US practice ─ Inconsistent use of diagnostic imaging─ Mandatory hospitalizations─ Mostly open surgery
![Page 25: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/25.jpg)
Evidence Gaps
• “Selected” patients─ Surgeons determined who was approached─ None with CT perforation or appendicolith─ Perforation rate in surgical arm of APPAC <2%
•Not typical US practice ─ Inconsistent use of diagnostic imaging─ Mandatory hospitalizations─ Mostly open surgery
• Little uptake of antibiotics in US
![Page 26: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/26.jpg)
….So Why Rock the Boat?
![Page 27: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/27.jpg)
….So Why Rock the Boat?
![Page 28: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/28.jpg)
….So Why Rock the Boat?
![Page 29: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/29.jpg)
….So Why Rock the Boat?
![Page 30: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/30.jpg)
![Page 31: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/31.jpg)
![Page 32: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/32.jpg)
![Page 33: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/33.jpg)
![Page 34: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/34.jpg)
Which treatment will get me back to work sooner and cost me less?
![Page 35: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/35.jpg)
![Page 36: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/36.jpg)
![Page 37: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/37.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
![Page 38: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/38.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
![Page 39: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/39.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
![Page 40: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/40.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
Safety
![Page 41: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/41.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
Safety
Time in healthcare
![Page 42: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/42.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
Safety
Time in healthcare
Which patients are most likely to have a successful outcome with antibiotics?
![Page 43: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/43.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
Safety
Time in healthcare
Which patients are most likely to have a successful outcome with antibiotics?
Appendicolith subgroup
![Page 44: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/44.jpg)
Are antibiotics as effective as appendectomy for appendicitis?
General health status
Clinical outcomes
Safety
Time in healthcare
Which patients are most likely to have a successful outcome with antibiotics?
Appendicolith subgroup
A Pragmatic Trial
![Page 45: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/45.jpg)
Population
![Page 46: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/46.jpg)
Population
• Adults with imaging confirmed appendicitis
─ Perforation and appendicolith allowed
![Page 47: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/47.jpg)
Population
• Adults with imaging confirmed appendicitis
─ Perforation and appendicolith allowed
• Excluded
─ Abscess, free air, diffuse peritonitis, septic shock
─ Ileocolectomy likely b/c of severe phlegmon
─ Pregnancy
─ Both treatments are not an option:─ Contraindication─ Allergies─ Immunocompromised
![Page 48: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/48.jpg)
Intervention and Comparator
![Page 49: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/49.jpg)
Intervention and Comparator
Antibiotics
• IV for at least 24 hours, then pills-total 10 days─ Guidelines for intra-abdominal infections
• Either hospitalized or discharged from the ED after receiving IV antibiotics
• Standard discharge criteria
• Appendectomy recommended for development of diffuse peritonitis/septic shock at any time or for worsening signs and symptoms after 48 hours
Appendectomy
• Laparoscopic and open-technique not standardized.
![Page 50: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/50.jpg)
“Am I going to feel better?” EuroQol-5D
![Page 51: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/51.jpg)
“Am I going to feel better?” EuroQol-5D
• What is the EQ5D?
![Page 52: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/52.jpg)
“Am I going to feel better?” EuroQol-5D
• What is the EQ5D?
![Page 53: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/53.jpg)
“Am I going to feel better?” EuroQol-5D
• What is the EQ5D?
• Why EQ5D?
![Page 54: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/54.jpg)
“Am I going to feel better?” EuroQol-5D
• What is the EQ5D?
• Why EQ5D?
• Why 30 days?
![Page 55: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/55.jpg)
“Am I going to feel better?” EuroQol-5D
• What is the EQ5D?
• Why EQ5D?
• Why 30 days?
• Self report of fever, right sided pain and tenderness by 7, 14, and 30 days
![Page 56: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/56.jpg)
Secondary outcomes
![Page 57: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/57.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
![Page 58: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/58.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events
![Page 59: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/59.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events─ A subset were Serious Adverse Events (for DSMB reporting)
![Page 60: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/60.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events─ A subset were Serious Adverse Events (for DSMB reporting)
• Perforation (described by surgeon or pathology report)
![Page 61: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/61.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events─ A subset were Serious Adverse Events (for DSMB reporting)
• Perforation (described by surgeon or pathology report)
• ED and urgent care visits
![Page 62: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/62.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events─ A subset were Serious Adverse Events (for DSMB reporting)
• Perforation (described by surgeon or pathology report)
• ED and urgent care visits
• Hospitalization days
![Page 63: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/63.jpg)
Secondary outcomes
• Appendectomy (any indication) in the antibiotics group
• NSQIP-defined morbidity events─ A subset were Serious Adverse Events (for DSMB reporting)
• Perforation (described by surgeon or pathology report)
• ED and urgent care visits
• Hospitalization days
• Days of missed work for patient and/or caregiver
![Page 64: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/64.jpg)
Methods: Analysis
• Intention-to-treat analysis, appendicolith subgroup pre-specified
• Non-inferiority─ Rule out an EQ-5D difference as small as 0.05
─ Secondary “treated per protocol” analysis
• Binomial regression-relative risks, Poisson regression (rate ratio) for count data, linear regression for continuous outcomes.
• Kaplan Meier-based cumulative incidence curve for appendectomy through 90 days
![Page 65: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/65.jpg)
We didn’t expect to be here today…
![Page 66: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/66.jpg)
We didn’t expect to be here today…
• Main analytic outcome time point- 30 days
![Page 67: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/67.jpg)
We didn’t expect to be here today…
• Main analytic outcome time point- 30 days
• Planned to focus on all outcomes at 1 year, finished recruitment in February
![Page 68: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/68.jpg)
We didn’t expect to be here today…
• Main analytic outcome time point- 30 days
• Planned to focus on all outcomes at 1 year, finished recruitment in February
![Page 69: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/69.jpg)
We didn’t expect to be here today…
• Main analytic outcome time point- 30 days
• Planned to focus on all outcomes at 1 year, finished recruitment in February
![Page 70: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/70.jpg)
![Page 71: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/71.jpg)
![Page 72: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/72.jpg)
![Page 73: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/73.jpg)
American College of Surgeons Clinical Congress October 5, 2020
Presented on behalf of the CODA Collaborative by;
David R. Flum, MD MPH and Giana H. Davidson, MD MPH
Department of Surgery
University of Washington
Seattle, WA
The CODA Collaborative
![Page 74: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/74.jpg)
Recruitment and Retention
![Page 75: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/75.jpg)
Recruitment and Retention
8168 Adults with imaging confirmed appendicitis
![Page 76: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/76.jpg)
Recruitment and Retention
4% “missed”
8168 Adults with imaging confirmed appendicitis
![Page 77: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/77.jpg)
Recruitment and Retention
~10% excluded for appendix-related reasons
4% “missed”
8168 Adults with imaging confirmed appendicitis
~10% excluded for other clinical reasons
![Page 78: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/78.jpg)
Recruitment and Retention
~10% excluded for appendix-related reasons
4% “missed”
8168 Adults with imaging confirmed appendicitis
~10% excluded for other clinical reasons
1.2% clinician deemed “ineligible” beyond these criteria
![Page 79: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/79.jpg)
Recruitment and Retention
~10% excluded for appendix-related reasons
4% “missed”
31% of eligible randomized
8168 Adults with imaging confirmed appendicitis
~10% excluded for other clinical reasons
1.2% clinician deemed “ineligible” beyond these criteria
![Page 80: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/80.jpg)
Recruitment and Retention
~10% excluded for appendix-related reasons
4% “missed”
31% of eligible randomized
8168 Adults with imaging confirmed appendicitis
~10% excluded for other clinical reasons
1.2% clinician deemed “ineligible” beyond these criteria
![Page 81: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/81.jpg)
Sex (male) 63%
AgeMean18-2950+
38 years31%19%
RaceWhite
Multiple/otherBlack/African American
AsianAmerican Indian/Alaska Native
Native Hawaiian/Pacific Islander
62%24%9%6%1%
0.5%Language (Spanish) 34%
InsuranceCommercial
Medicaid42%18%
Demographics
![Page 82: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/82.jpg)
Overall (n=1552)
BMI mean(range) 29 (15.8-62)
Duration of symptoms (days) mean1.7
Report of fever (%) 24%
Initial WBC mean 13.1K
Characteristics at ED presentation
![Page 83: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/83.jpg)
Overall (n=1552)
BMI mean(range) 29 (15.8-62)
Duration of symptoms (days) mean1.7
Report of fever (%) 24%
Initial WBC mean 13.1K
CT scanning in 96% (n=1493)
Characteristics at ED presentation
![Page 84: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/84.jpg)
Overall (n=1552)
BMI mean(range) 29 (15.8-62)
Duration of symptoms (days) mean1.7
Report of fever (%) 24%
Initial WBC mean 13.1K
Appendix maximum diameter (mm) 11.4
Appendicolith 27%
Peri-appendiceal fat stranding 75%
Perforation (or ambiguous) 3%
Periappendiceal or pelvic fluid 26%
CT scanning in 96% (n=1493)
Characteristics at ED presentation
![Page 85: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/85.jpg)
Treatment
![Page 86: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/86.jpg)
Treatment
• Antibiotics-assigned─ 47% ED-to-home
79% of these discharged w/i 24 hours
─ Outpatient approach varied from 0-81% across sites
![Page 87: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/87.jpg)
Treatment
• Antibiotics-assigned─ 47% ED-to-home
79% of these discharged w/i 24 hours
─ Outpatient approach varied from 0-81% across sites
─ Time from randomization to d/c (overall)-1.3 days
─ Index LoS of >5 days-5%
![Page 88: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/88.jpg)
Treatment
• Antibiotics-assigned─ 47% ED-to-home
79% of these discharged w/i 24 hours
─ Outpatient approach varied from 0-81% across sites
─ Time from randomization to d/c (overall)-1.3 days
─ Index LoS of >5 days-5%
─ 11% receive another course of antibiotics within 90 days
![Page 89: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/89.jpg)
Treatment
• Antibiotics-assigned─ 47% ED-to-home
79% of these discharged w/i 24 hours
─ Outpatient approach varied from 0-81% across sites
─ Time from randomization to d/c (overall)-1.3 days
─ Index LoS of >5 days-5%
─ 11% receive another course of antibiotics within 90 days
• Appendectomy-assigned─ 94% had surgery at index, 97% laparoscopic
![Page 90: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/90.jpg)
Treatment
• Antibiotics-assigned─ 47% ED-to-home
79% of these discharged w/i 24 hours
─ Outpatient approach varied from 0-81% across sites
─ Time from randomization to d/c (overall)-1.3 days
─ Index LoS of >5 days-5%
─ 11% receive another course of antibiotics within 90 days
• Appendectomy-assigned─ 94% had surgery at index, 97% laparoscopic
─ Time from randomization to d/c (overall)-1.3 days
─ Index LoS of >5 days-2%
![Page 91: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/91.jpg)
Non-inferiority of EQ-5D at 30 days
-.075 -.05 -.025 0.0 .025 .05 .075
Non-inferiority margin= -.05
Favors
Appendectomy
First
Favors
Antibiotics
First
Difference between groups in 1-mo quality of life
CODA: antibiotics are non-inferior
![Page 92: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/92.jpg)
Non-inferiority of EQ-5D at 30 days
Mean difference overall: 0.01 (-0.001,0.03) Appendicolith: -0.01 (-0.03,0.02) Not appendicolith: 0.02 (0.003,0.03)
-.075 -.05 -.025 0.0 .025 .05 .075
Non-inferiority margin= -.05
Favors
Appendectomy
First
Favors
Antibiotics
First
Difference between groups in 1-mo quality of life
CODA: antibiotics are non-inferior
![Page 93: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/93.jpg)
Self-report of Fever, RLQ Pain and Tenderness
30 Days14 Days7 Days
![Page 94: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/94.jpg)
Self-report of Fever, RLQ Pain and Tenderness
30 Days14 Days7 Days
![Page 95: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/95.jpg)
Self-report of Fever, RLQ Pain and Tenderness
30 Days14 Days7 Days
RelR=Relative Risk (95% CI)
![Page 96: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/96.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Ap
pen
dec
tom
y, C
um
ula
tive
Inci
den
ce
![Page 97: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/97.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
Ap
pen
dec
tom
y, C
um
ula
tive
Inci
den
ce
![Page 98: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/98.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
Appendicolith-41%A
pp
end
ecto
my,
Cu
mu
lati
ve In
cid
ence
![Page 99: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/99.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
No appendicolith-25%
Appendicolith-41%A
pp
end
ecto
my,
Cu
mu
lati
ve In
cid
ence
![Page 100: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/100.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
No appendicolith-25%
Appendicolith-41%A
pp
end
ecto
my,
Cu
mu
lati
ve In
cid
ence
48 hours
Overall 11% (9-14%)
No appendicolith 8% (5-10%)
Appendicolith 22% (16-27%)
![Page 101: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/101.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
No appendicolith-25%
Appendicolith-41%A
pp
end
ecto
my,
Cu
mu
lati
ve In
cid
ence
48 hours
Overall 11% (9-14%)
No appendicolith 8% (5-10%)
Appendicolith 22% (16-27%)
30 days
Overall 20% (17-23%)
No appendicolith 16% (13-19%)
Appendicolith 31% (25-37%)
![Page 102: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/102.jpg)
+
++++++ +++++++++++++++++++++++++++++++
+++++++++ ++++++ ++++
+ +++++++++++++++++++++++++++++++++++++++
+
++++++ ++++++++++++++++++++++++++
++++++++ ++++ +++
+ +++++++++++++++++++++++++++++++++
+
+++++++++
+ ++ +
+++++++++++++
48 Hours 30 Days 90 Days
0.11 (0.09, 0.14) 0.20 (0.17, 0.23) 0.29 (0.26, 0.32)
0.08 (0.05, 0.10) 0.16 (0.13, 0.19) 0.25 (0.21, 0.29)
0.22 (0.16, 0.27) 0.31 (0.25, 0.37) 0.41 (0.33, 0.47)
Cumulative Incidence
(95% CI)
Overall
No Appendicolith
Appendicolith
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0 14 28 42 56 70 84
Days Since Randomization
App
en
decto
my
Cu
mu
lative
In
cid
en
ce
Strata + + +Overall No Appendicolith Appendicolith
Appendectomy Cumulative Incidence by Appendicolith Status
776 616 589 542 518 499 485
564 470 448 411 394 381 371
212 146 141 131 124 118 114Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Number at risk
0 141 151 170 184 203 212
0 79 86 102 112 125 131
0 62 65 68 72 78 81Appendicolith
No Appendicolith
Overall
0 14 28 42 56 70 84
Days Since Randomization
Str
ata
Cumulative number of events
Overall-29%
No appendicolith-25%
Appendicolith-41%A
pp
end
ecto
my,
Cu
mu
lati
ve In
cid
ence
48 hours
Overall 11% (9-14%)
No appendicolith 8% (5-10%)
Appendicolith 22% (16-27%)
30 days
Overall 20% (17-23%)
No appendicolith 16% (13-19%)
Appendicolith 31% (25-37%)
90 days
Overall 29% (26-32%)
No appendicolith 25% (21-29%)
Appendicolith 41% (33-47%)
![Page 103: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/103.jpg)
Any hospitalization (any reason) after index within 90 days
![Page 104: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/104.jpg)
Any hospitalization (any reason) after index within 90 days
![Page 105: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/105.jpg)
Any hospitalization (any reason) after index within 90 days
RelR=Relative Risk (95% CI)
![Page 106: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/106.jpg)
Any ED/UC visits After Index within 90 days
![Page 107: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/107.jpg)
Any ED/UC visits After Index within 90 days
![Page 108: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/108.jpg)
Any ED/UC visits After Index within 90 days
RelR=Relative Risk (95% CI)
![Page 109: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/109.jpg)
Differences in Days in Healthcare/Away from Work
![Page 110: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/110.jpg)
NSQIP morbidity events (per 100 patients) within 90 days
![Page 111: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/111.jpg)
NSQIP morbidity events (per 100 patients) within 90 days
![Page 112: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/112.jpg)
NSQIP morbidity events (per 100 patients) within 90 days
RR=Rate Ratio (95% CI)
![Page 113: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/113.jpg)
Serious Adverse Events (at least one) within 90 Days
![Page 114: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/114.jpg)
Serious Adverse Events (at least one) within 90 Days
![Page 115: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/115.jpg)
Serious Adverse Events (at least one) within 90 Days
RR=Rate Ratio (95% CI)
![Page 116: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/116.jpg)
Surgical Site Infection or Abscess within 90 Days
![Page 117: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/117.jpg)
Surgical Site Infection or Abscess within 90 Days
![Page 118: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/118.jpg)
Surgical Site Infection or Abscess within 90 Days
RR=Rate Ratio (95% CI)
![Page 119: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/119.jpg)
Percutaneous Drainage within 90 Days
![Page 120: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/120.jpg)
Percutaneous Drainage within 90 Days
![Page 121: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/121.jpg)
Percutaneous Drainage within 90 Days
RR=Rate Ratio (95% CI)
![Page 122: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/122.jpg)
Neoplasm
![Page 123: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/123.jpg)
Neoplasm
• 9 Identified by 90 days
![Page 124: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/124.jpg)
Neoplasm
• 9 Identified by 90 days ─ 7 in appendectomy arm and 2 in antibiotic arm
![Page 125: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/125.jpg)
Neoplasm
• 9 Identified by 90 days ─ 7 in appendectomy arm and 2 in antibiotic arm
─ 8 were carcinomas and 1 was a mucocele
![Page 126: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/126.jpg)
Neoplasm
• 9 Identified by 90 days ─ 7 in appendectomy arm and 2 in antibiotic arm
─ 8 were carcinomas and 1 was a mucocele
• Mean age 47 (SD 17), with a range of 21-74 years
![Page 127: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/127.jpg)
Neoplasm
• 9 Identified by 90 days ─ 7 in appendectomy arm and 2 in antibiotic arm
─ 8 were carcinomas and 1 was a mucocele
• Mean age 47 (SD 17), with a range of 21-74 years
![Page 128: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/128.jpg)
Limitations
![Page 129: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/129.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
![Page 130: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/130.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses
![Page 131: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/131.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
![Page 132: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/132.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
─ Indication for appendectomy in antibiotics arm
![Page 133: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/133.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
─ Indication for appendectomy in antibiotics arm
─ ED-to-home antibiotics: confounding and selection bias
![Page 134: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/134.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
─ Indication for appendectomy in antibiotics arm
─ ED-to-home antibiotics: confounding and selection bias
• Lack of blinding and subjective outcomes
![Page 135: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/135.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
─ Indication for appendectomy in antibiotics arm
─ ED-to-home antibiotics: confounding and selection bias
• Lack of blinding and subjective outcomes─ Parallel observational study reported separately
![Page 136: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/136.jpg)
Limitations
• Early report: appendectomy for recurrence likely to increase with longer follow up
• Pragmatic trials: strengths and weaknesses─ Technique not standardized
─ Indication for appendectomy in antibiotics arm
─ ED-to-home antibiotics: confounding and selection bias
• Lack of blinding and subjective outcomes─ Parallel observational study reported separately
• Sex distribution
![Page 137: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/137.jpg)
Summary of findings
![Page 138: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/138.jpg)
Summary of findings
• “Will I Feel Better?”
![Page 139: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/139.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
![Page 140: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/140.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
![Page 141: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/141.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
![Page 142: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/142.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
![Page 143: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/143.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
![Page 144: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/144.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
• “Safety?”
![Page 145: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/145.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
• “Safety?”─ Non-appendicolith group: no difference in safety/complications
![Page 146: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/146.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
• “Safety?”─ Non-appendicolith group: no difference in safety/complications
─ Appendicolith group: higher risk of complications and safety events with antibiotics
![Page 147: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/147.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
• “Safety?”─ Non-appendicolith group: no difference in safety/complications
─ Appendicolith group: higher risk of complications and safety events with antibiotics
• “Time in healthcare/Return to work?”
![Page 148: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/148.jpg)
Summary of findings
• “Will I Feel Better?”─ At least at 30 days, antibiotics non-inferior based on a health status measure
─ Time until resolution of signs and symptoms similar between groups
─ If receiving antibiotics,
• ~3 in 10 overall undergo appendectomy
• ~4 in 10 if there is an appendicolith
• “Safety?”─ Non-appendicolith group: no difference in safety/complications
─ Appendicolith group: higher risk of complications and safety events with antibiotics
• “Time in healthcare/Return to work?”─ Antibiotics: more visits (ED and hospital) but quicker return to work
![Page 149: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/149.jpg)
Acknowledgments
![Page 150: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/150.jpg)
Acknowledgments
Research reported in this presentation was funded through a Patient-Centered Outcomes Research Institute® (PCORI®)
Award (PCS-1409-24099)
![Page 151: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/151.jpg)
Acknowledgments
Research reported in this presentation was funded through a Patient-Centered Outcomes Research Institute® (PCORI®)
Award (PCS-1409-24099)
NIH NIDDK T32 grant: 5T32DK070555-09
![Page 152: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/152.jpg)
Acknowledgments
Research reported in this presentation was funded through a Patient-Centered Outcomes Research Institute® (PCORI®)
Award (PCS-1409-24099)
NIH NIDDK T32 grant: 5T32DK070555-09
AHRQ grant to fund CERTAIN: R01HS22959
![Page 153: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/153.jpg)
Acknowledgments
Research reported in this presentation was funded through a Patient-Centered Outcomes Research Institute® (PCORI®)
Award (PCS-1409-24099)
NIH NIDDK T32 grant: 5T32DK070555-09
AHRQ grant to fund CERTAIN: R01HS22959
The views presented in this presentation are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee
![Page 154: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/154.jpg)
Acknowledgements
We are especially appreciative of the generosity and altruism of all the participants who participated in this trial.
![Page 155: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/155.jpg)
Executive Committee: Bonnie Bizzell, MBA, MEd (Chair, Patient Advisory Board);
Bryan Comstock, MS (Operations Director, Data Coordinating Center); Giana
Davidson, MD MPH (Chair, Clinical Coordinating Center); Erin Fannon (Senior Project
Manager); David R. Flum, MD, MPH (Co-Principal Investigator); Patrick J. Heagerty,
PhD, MS (Director, Data Coordinating Center); Larry G. Kessler, ScD (Chair, Executive
Committee); Anusha Krishnadasan, PhD (Project Manager, California); Danielle C.
Lavallee, PharmD, PhD (Director, Stakeholder Coordinating Center); Sarah Monsell,
MS (Lead Biostatistician); Kelsey Pullar, MPH (Research Coordinator Lead); David A. Talan, MD (Co-Principal Investigator); Erika Wolff, PhD (UW)
Patient Advisory Board: Meridith Weiss, Kimberly Deeney, Heather VanDusen, Elliott Skopin, Mary Guiden, Miriam Hernandez
National Advisory Board: Emily E. Anderson, PhD, MPH; Darrell A. Campbell, Jr.,
MD; Fergal Fleming, MD; David B. Hoyt, MD; J.J. Tepas III, MD (Deceased); Richard W. Whitten, MD; SreyRam Kuy, MD; Daniel S. Lessler, MD, MHA
Data Safety and Monitoring Board: Karla Ballman, PhD; Thomas Diflo, MD; Bruce
Wolfe, MD; Arden Morris, MD; Donald Yealy, MD. Patient Advisors: Kathleen O’Connor,
EdD; Olga Owens, N-PC
![Page 156: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/156.jpg)
CODA Collaborative
East Coast: Bellevue Hospital Center New York
University School of MedicineTisch Hospital New York University
Langone Medical CenterBeth Israel Deaconess Medical
Center Boston University Medical Center
Columbia University Medical Center
Weill Cornell MedicineMaine Medical Center
South: University of Mississippi
Vanderbilt Medical CenterUniversity of Texas Lyndon B. Johnson General HospitalUniversity of Texas Health Science Center at Houston
Midwest: University of Michigan
The Ohio State University WexnerMedical Center
Henry Ford Health SystemsUniversity of Iowa
Rush University Medical Center
West: University of Washington Medical
CenterHarborview Medical Center
Virginia Mason Medical CenterSwedish Medical Center- First Hill
Providence Regional Medical Center- Everett
Madigan Army Medical CenterHarbor-University of California Los
Angeles Medical CenterOlive View-University of California
Los Angeles Medical CenterUniversity of Colorado Denver
![Page 157: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/157.jpg)
![Page 158: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/158.jpg)
CODA: Site InvestigatorsBellevue NYU School of MedicineOnaona Gurney, MDWilliam Chiang, MDPatricia Ayoung-Chee, MD, MPH
Beth Israel Deaconess Medical CenterCharles Parsons, MDNathan Shapiro, MD, MPH
Boston University Medical CenterThurston Drake, MD, MPH Sabrina Sanchez, MD, MPH
Columbia University Medical CenterKatherine Fischkoff, MDAleksandr Tichter, MD, MS
Harbor-UCLA Medical CenterDaniel A. DeUgarte, MDAmy Kaji, MD, PhD
Harborview Medical CenterJoe Cuschieri, MDAmber K Sabbatini, MD, MPHHeather Evans, MD
Henry Ford Health HospitalJeffrey Johnson, MD Joe Patton, MD
Madigan Army Medical Center Vance Sohn, MDKaren McGrane, MD
Maine Medical CenterDamien Carter, MD
The Ohio State University Jon Wisler, MDAmy Rushing, MD
Olive View-UCLA Medical CenterDarin Saltzman, MD, PhDDavid Talan, MD Gregory Moran, MD
Providence Regional Medical Center Careen Foster, MDBrandon Tudor, MD
Rush University Medical CenterThea P Price, MD
Swedish Medical CenterKatherine Mandell, MD, MPH
Tisch NYU Langone Medical CenterOnaona Gurney, MDWilliam Chiang, MD
UCHealth University of Colorado Lisa Ferrigno, MD, MPHMatthew Salzberg, MD, MBA
University of Iowa HealthcareDionne Skeete, MDBrett Faine, PharmD, MS
University of Michigan Medical CenterPauline Park, MDHasan Alam, MD
University of Mississippi Matthew Kutcher, MD, MSAlan Jones, MD
University of Texas at HoustonLillian Kao, MD, MS
University of Texas LBJMike Liang, MD
University of WashingtonGiana H. Davidson, MD, MPHAmber K Sabbatini, MD, MPH
Vanderbilt University Medical CenterWesley Self, MD, MPHCallie Thompson, MD
Virginia Mason Medical CenterAbigal Wiebusch, MDJuliana Yu, MD
Weill Cornell Medical CenterRobert Winchell, MDSunday Clark, ScD, MPH
![Page 159: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/159.jpg)
CODA “take home points”
![Page 160: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/160.jpg)
CODA “take home points”
• Largest trial to date
![Page 161: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/161.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
![Page 162: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/162.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
![Page 163: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/163.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
![Page 164: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/164.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
![Page 165: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/165.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
• Complication rate
![Page 166: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/166.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
• Complication rate
─ Higher overall for antibiotics-driven by appendicolith subgroup
![Page 167: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/167.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
• Complication rate
─ Higher overall for antibiotics-driven by appendicolith subgroup
─ No increase in complications in non-appendicolith group
![Page 168: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/168.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
• Complication rate
─ Higher overall for antibiotics-driven by appendicolith subgroup
─ No increase in complications in non-appendicolith group
• Decision makers must weigh characteristics, preferences and circumstances: “one size does not fit all”
![Page 169: The CODA Collaborative](https://reader031.vdocuments.site/reader031/viewer/2022020916/61a7ff879976101fa63c4e91/html5/thumbnails/169.jpg)
CODA “take home points”
• Largest trial to date
─ Includes historically “at risk” patients
• ED-to-home antibiotics-used in 47%
• 3-in-10 undergo appendectomy (higher in the appendicolith group) / 7-in-10 avoid surgery
• Multiple outcomes favor one treatment or the other
• Complication rate
─ Higher overall for antibiotics-driven by appendicolith subgroup
─ No increase in complications in non-appendicolith group
• Decision makers must weigh characteristics, preferences and circumstances: “one size does not fit all”
• Antibiotics for appendicitis: a good choice for some, probably not all